Strategic partnership forms single-source solution for biopharma

By Melissa Fassbender

- Last updated on GMT

(Image: CSSi Life Sciences)
(Image: CSSi Life Sciences)

Related tags Infectious disease

CSSi LifeSciences and BioMARC have announced a strategic partnership to provide 'fully cohesive product development and support' for vaccine and biologic development. 

CSSi LifeSciences, an industry partner for discovery and commercialization of biologics and vaccines, announced the strategic partnership with the Biopharmaceutical Manufacturing and Academic Resource Center (BioMARC​), a nonprofit contract manufacturing service run by Colorado State University.

"The goal of the partnership between CSSi LifeSciences and BioMARC is to provide our clients with the services, resources and solutions needed to help meet their needs for innovation and development programs related to the prevention, management and treatment of infectious diseases​," Jim Sergi, president, CSSi LifeSciences, told

"Such capabilities focus on development and manufacturing expertise, addressing the tough problems and challenging tasks in this field that do not exist broadly in the biopharma environment," ​Raymond Goodrich, PhD, Executive Director, Infectious Disease Research Center at BioMarc, added.

The companies' expertise ranges from preclinical testing, to cGMP production and on through late stage clinical trials as well as commercialization.

Dennis Pierro, PhD, Director, BioMARC, told us the benefit to clients is in the "fully cohesive product development support and regulatory guidance​," now available as part of the strategic partnership.

The official announcement was made at the CSSi LifeSciences Partnering Forum 2017, which took place yesterday at the J.P. Morgan 35th Annual Healthcare Conference.

Related news

Show more

Related products

show more

Pulmonary Delivery of Orally Inhaled Therapeutics

Pulmonary Delivery of Orally Inhaled Therapeutics

Content provided by Catalent Pharma Solutions | 19-Oct-2023 | Business Advice

New classes and indications of orally inhaled therapeutics are rapidly expanding, with the development pipeline increasingly featuring both large and small...

Addressing Challenges with Clinical In-Use Testing

Addressing Challenges with Clinical In-Use Testing

Content provided by Lonza | 12-Oct-2023 | White Paper

Lonza Drug Product expert Léa Sorret PhD explores Clinical In-Use Testing of Biotherapeutics in this white paper. Léa shares her expertise and describes...

Manufacturing Drugs with Highly Potent APIs

Manufacturing Drugs with Highly Potent APIs

Content provided by Altasciences | 28-Sep-2023 | White Paper

In this issue of The Altascientist, we examine the critical considerations for the safe and compliant manufacture of drugs with highly potent APIs (HPAPIs),...

Related suppliers

Follow us


View more